
The civil rights leader Rev. Jesse Jackson has been hospitalized, the Rainbow PUSH Coalition announced Wednesday evening.
Jackson, 84, has been admitted to the hospital and is under observation for progressive supranuclear palsy, a neurodegenerative condition, which he has been managing for a decade, the organization said in a statement.
"The family appreciates all prayers at this time," the group said.
Jackson was originally diagnosed with Parkinson's disease, however his PSP condition was confirmed in April, the organization said.
PSP is a rare neurological disorder which affects body movements, walking and balance, and eye movements, according to the National Institutes of Health. It is caused by damage to nerve cells in parts of the brain.
Jackson, a protege to the Rev. Martin Luther King Jr. who rose to prominence as one of the nation's foremost civil rights leaders and twice ran for U.S. president, stepped down in 2023 from the leadership of the Rainbow PUSH Coalition, which he founded.
LATEST POSTS
- 1
Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds - 2
Figure out How to Protect Your Gold Venture from Unpredictability - 3
Pick Your #1 Kind Of Treat - 4
Figure out How to Track the Establishment of New 5G Pinnacles - 5
A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
OpenAI launches ChatGPT Health to connect medical records, wellness apps
Indian Health Service is digging out of decades-old construction backlog for medical buildings
Exploiting Unsold Rams: May Be Less expensive Than You Suspect
ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
An Extended time of Self-Reflection: Self-awareness through Journaling
Exploring Programming Greatness: A Survey of \Easy to use Connection points\
A Manual for Pick Dependable Vehicle Rental Administrations For 2024
Bayer reports positive results for blood thinner after 2023 setback













